CSF metabolomics alterations after aneurysmal subarachnoid hemorrhage: what do we know?

PurposeThe purpose of this mini review is to describe metabolomics in cerebrospinal fluid (CSF) and its potential in aneurysmal subarachnoid hemorrhage (aSAH). In brain injury, patients' micro dialysis enables detecting biochemical change in brain tissue. Indicators for ischemia were detected such as lactate, pyruvate, glucose, and glutamate. In aSAH patients, the pathophysiology and the factor for poor outcome are not completely understood yet. Routine use of biomarkers in CSF, particularly in aSAH patients, is still lacking.MethodsThis mini review was performed on the role of metabolomics alterations after aneurysmal subarachnoid hemorrhage.ResultsWe identified five clinical studies that addressed metabolomics in patients with aneurysmal subarachnoid hemorrhage.ConclusionThere is increasing evidence suggesting that biomarkers can give insight in the pathogenesis and can serve as an outcome predictor. In this mini review, we present a brief overview of metabolomics profiling in neuroscience and wish to discuss the predictive and therapeutic value in aSAH patients.

Automated summary

This mini review focuses on discussing the application and potential value of metabolomics in aneurysmal subarachnoid hemorrhage (aSAH). It is shown that patients' microdialysis enables the detection of biochemical changes in brain tissue. However, the pathophysiology and factors for poor outcome in aSAH patients are not completely understood yet. Routine use of biomarkers in cerebrospinal fluid, particularly in aSAH patients, is still lacking.